Repeated injections of nicergoline increase the nerve growth factor level in the aged rat brain

Japanese Journal of Pharmacology

Volumn 76, Issue 3, 1998, Pages 321-323

  Nishio, Takeshi ^a,b   Sunohara, Nobuhiko ^a   Furukawa, Shoei ^c   Akiguchi, Ichiro ^b   Kudo, Yukitsuka ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Aged rat brain; Nerve growth factor; Nicergoline

Indexed keywords

NERVE GROWTH FACTOR; NICERGOLINE;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; FRONTAL CORTEX; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT;

EID: 0031899243     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.76.321     Document Type: Article

References (14)

1. Thoenen H: The changing scene of neurotrophic factors. Trends Neurosci 14, 165-170 (1991)
2. Arcari G, Dorigotti L, Fregnan GB and Glasser AH: Vasodilating and alpha-receptor blocking activity of a new ergoline derivative. Br J Pharmacol 34, 700 (1968)
3. Le Poncin-Lafitte M, Grosdemouge C, Duterte D and Rapin JR: Simultaneous study of hemodynamic, metabolic and behavioral sequelae in a model of cerebral ischemia in aged rats; effects of nicergoline. Gerontology 30, 109-119 (1984)
4. Heitz C, Descombes JJ, Miller RC and Stoclet JC: α-Adrenoreceptor antagonistic and calcium antagonistic effects of nicergoline in the rat isolated aorta. Eur J Pharmacol 123, 279-285 (1986)
5. 2+ channels in rat isolated hippocampal CA1 pyramidal neurons. Br J Pharmacol 100, 705-710 (1990)
6. Matsuoka Y, Fukushima T, Iwata H, Matsumoto M, Shibutani Y, Kawashima K, Kudo Y and Ishida R: Inhibitory action of nicergoline and its major metabolites on acetylcholinesterase activity in rat and mouse brain. In Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Disease, Edited by Nagatsu T, Fisher A and Yoshida H, Vol 2, pp 415-419, Plenum Press, New York (1990)
7. Ogawa N, Asanuma M, Hirata H, Kondo Y, Kawada Y and Mori A: Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch Gerontol Geriatr 16, 103-110 (1993)
8. Nishio T, Akiguchi I and Furukawa S: Detailed distribution of nerve growth factor determined by a highly sensitive enzyme immunoassay. Exp Neurol 116, 76-84 (1992)
9. 1A-adrenergic receptor. J Biol Chem 266, 6365-6369 (1991)
10. Tuttle JB, Etheridge R and Creedon DJ: Receptor-mediated stimulation and inhibition of nerve growth factor secretion by vascular smooth muscle. Exp Cell Res 208, 350-361 (1993)
11. Zafra F, Lindholm D, Castren E, Hartikka J and Thoenen H: Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J Neurosci 12, 4793-4799 (1992)
12. Moretti A, Carfagna N, Caccia C, Carpentieri M, Amico A, Marchi G and Trunzo F: Neurochemical effects of ergoline derivatives. In Proof of Therapeutical Effectiveness of Nootropic and Vasoactive Drugs; Advances in Clinical and Experimental Nicergoline Research, Edited by Heidrich H, pp 103-110, Springer-Verlag, Berlin, Heidelberg, New York and Tokyo (1985)
13. Furukawa S, Furukawa Y, Satoyoshi E and Hayashi K: Regulation of nerve growth factor synthesis/secretion by catecholamine in cultured mouse astroglial cells. Biochem Biophys Res Commun 147, 1048-1054 (1987)
14. Furukawa Y, Furukawa S, Satoyoshi E and Hayashi K: Catecholamines increase nerve growth factor mRNA contents in both mouse astroglial cells and fibroblasts cells. FEBS Lett 247, 463-467 (1989)